<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00947492</url>
  </required_header>
  <id_info>
    <org_study_id>2009-07</org_study_id>
    <secondary_id>2009-A00247-50</secondary_id>
    <nct_id>NCT00947492</nct_id>
  </id_info>
  <brief_title>Monitoring Epstein-Barr Virus (EBV) Load in Rheumatoid Arthritis Patients Treated With New Immunosuppressive Drugs</brief_title>
  <official_title>Monitoring EBV Load in Rheumatoid Arthritis Patients Treated With New Immunosuppressive Drugs ; Orencia* (Abatacept) and RoActemra* (Tocilizumab).</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique Hopitaux De Marseille</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique Hopitaux De Marseille</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      PBMNC DNA is considered a limit above which patients will develop EBV associated post&#xD;
      transplant lymphoproliferative disorder.&#xD;
&#xD;
      we showed that methotrexate tended to decrease EBV load over time, but this did not reach&#xD;
      significance and that TNFa inhibitors did not significantly modify EBV load over time.&#xD;
&#xD;
      Our objective is to monitor Epstein Barr Virus load over time in patients with Rheumatoid&#xD;
      arthritis under Orencia* (abatacept) or RoActemra* (tocilizumab), to detect possible&#xD;
      immunosuppression associated EBV dysregulation, as seen in post transplant&#xD;
      lymphoproliferative disease.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Current treatment of RA routinely includes potentially immunosuppressive medications like&#xD;
      methotrexate and TNFa inhibitors. New immunosuppressive drugs are at disposal, Orencia*&#xD;
      (abatacept) which is a T cell co-stimulation modulator (CTLA4Ig) and RoActemra*&#xD;
      (tocilizumab), an antibody against IL6 receptor. In solid organ transplant recipients under&#xD;
      immunosuppressants, emergence of lymphoma can be predicted by monitoring EBV load in&#xD;
      peripheral blood mononuclear cells (PBMNCs). EBV load above 1000 copies per 500 ng PBMNC DNA&#xD;
      is considered a limit above which patients will develop EBV associated post transplant&#xD;
      lymphoproliferative disorder, a condition characterized by polyclonal EBV positive B&#xD;
      lymphocyte proliferation which can evolve into EBV positive B cell lymphoma .&#xD;
&#xD;
      In a first study, we showed that Rheumatoid arthritis patients have 10 fold systemic EBV&#xD;
      overload, very similar to that observed in healthy organ transplant recipients. More&#xD;
      recently, we showed that methotrexate tended to decrease EBV load over time, but this did not&#xD;
      reach significance and that TNFa inhibitors did not significantly modify EBV load over time.&#xD;
&#xD;
      Our objective is to monitor Epstein Barr Virus load over time in patients with Rheumatoid&#xD;
      arthritis under Orencia* (abatacept) or RoActemra* (tocilizumab), to detect possible&#xD;
      immunosuppression associated EBV dysregulation, as seen in post transplant&#xD;
      lymphoproliferative disease.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>June 2009</start_date>
  <completion_date type="Anticipated">December 2014</completion_date>
  <primary_completion_date type="Anticipated">September 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>to monitor Epstein Barr Virus load over time in patients with Rheumatoid arthritis under Orencia* (abatacept) or RoActemra* (tocilizumab)</measure>
    <time_frame>3 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>to detect possible immunosuppression associated EBV dysregulation, as seen in post transplant lymphoproliferative disease</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Venous blood sample</intervention_name>
    <description>Venous blood sample twice a year during 3 years</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Rheumatoid arthritis patients&#xD;
&#xD;
          -  treated with new immunosuppressive drugs : Orencia* (abatacept) and RoActemra*&#xD;
             (tocilizumab)&#xD;
&#xD;
          -  Disease longer than one year&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Rheumatoid arthritis patients treated with ciclosporin in two years preceding the&#xD;
             study&#xD;
&#xD;
          -  Transplanted patients&#xD;
&#xD;
          -  Disease shorter than one year&#xD;
&#xD;
          -  Histories of lymphoma&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nathalie Balandraud</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assistance Publique Hopitaux De Marseille</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Assistance Publique-Hopitaux de Marseille</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>August 2014</verification_date>
  <study_first_submitted>July 27, 2009</study_first_submitted>
  <study_first_submitted_qc>July 27, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 28, 2009</study_first_posted>
  <last_update_submitted>August 27, 2014</last_update_submitted>
  <last_update_submitted_qc>August 27, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 28, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Rheumatoid Arthritis patients</keyword>
  <keyword>treated with new immunosuppressive drugs : Orencia* (abatacept) and RoActemra* (tocilizumab).</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

